Inovio Pharma upgraded by H.C. Wainwright with a new price target
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
H.C. Wainwright upgrades Inovio from Neutral to Buy with a $5.00 price target.
Historical context for INO
Across the 24 sessions after earlier INO headlines, the stock closed higher 13 times and lower 10 times, with a median move of 3.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INO | SPY |
|---|---|---|---|
| Nov 2, 2026 | INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) | +213.7% | -0.5% |
| Oct 21, 2026 | INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science | -21.3% | +0.5% |
| Sep 2, 2026 | INOVIO to Participate in Upcoming Investor Conferences | +2.3% | +0.4% |
| Aug 13, 2026 | Inovio Pharma upgraded by Jefferies with a new price targetand 1 other headline that session | +16.9% | +0.7% |
| Aug 5, 2026 | INOVIO to Report Second Quarter Financial Results on August 12, 2026 | +2.1% | -0.2% |
| Jul 30, 2026 | INOVIO Announces Pricing of $20.0 Million Public Offeringand 1 other headline that session | -36.9% | +1.7% |
Quantisnow market dataNASDAQ
INO
Inovio Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for INO
Full INO profile on Quantisnow Follow INO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time